University of Texas Health Science Center at San Antonio, 5623 Hamilton Wolfe, #712, San Antonio, TX 78240, USA.
Department of Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Pancreatology. 2018 Dec;18(8):862-867. doi: 10.1016/j.pan.2018.09.004. Epub 2018 Sep 18.
Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker which has been extensively evaluated and widely utilized primarily in diagnosing and prognosticating pancreaticobiliary malignancies. Levels may be significantly influenced and elevated in cases of benign biliary conditions however, especially in obstructive jaundice, thereby posing difficulty in distinguishing between benign and malignant cholestasis. A myriad of studies have focused on elucidating proper use and interpretation of CA 19-9 in pancreatic cancer as well as in the setting of cholestasis. These studies have demonstrated that many factors influence CA 19-9 values and various methods for interpreting CA 19-9 in obstructive jaundice have been proposed. With improvements in diagnostic imaging, advancements in endoscopic modalities, and likelihood that management will not change based on the results of the test, clinicians should be cautious when ordering CA 19-9 and consider the reasons for measuring the tumor marker.
糖类抗原 19-9（CA 19-9）是一种肿瘤标志物，已被广泛评估和应用，主要用于诊断和预测胰腺胆道恶性肿瘤。然而，在良性胆道疾病的情况下，CA 19-9 水平可能会受到显著影响并升高，尤其是在阻塞性黄疸的情况下，这使得良性和恶性胆汁淤积的鉴别变得困难。大量研究致力于阐明 CA 19-9 在胰腺癌和胆汁淤积中的正确使用和解释。这些研究表明，许多因素会影响 CA 19-9 的数值，并且已经提出了多种解释阻塞性黄疸中 CA 19-9 的方法。随着诊断成像的改进、内镜治疗方式的进步，以及管理可能不会根据检测结果改变的可能性，临床医生在开具 CA 19-9 检测时应谨慎，并考虑测量肿瘤标志物的原因。
